Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1147401

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1147401

Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases (I to IV), Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology), End User (Pharma, Biotech, CROs) - Global Forecast 2027

PUBLISHED:
PAGES: 254 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

The Global Clinical Trial Supplies market is projected to reach USD 5.7 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 9.7% during the forecast period of 2022 to 2027. Factors such a as globalization of clinical trials and growing R&D expenditure in pharmaceutical and biopharmaceutical companies are driving the market.

"The logistics and distribution segment accounted for the highest growth rate in the clinical trial supplies market, by service, during the forecast period"

In 2021, the logistics & distribution services segment accounted for the largest share of the clinical trial supplies market. Factors such as the globalization of clinical trials, expertise of supply companies in terms of therapeutic areas and geographical reach and the increasing number of trials involving temperature-sensitive products are driving the market.

"Oncology segment accounted for the largest share of the therapeutic area segment"

On the basis of therapeutic area, the clinical trial supplies market is divided into oncology, cardiovascular diseases, digestive disorders, infectious diseases, CNS & mental disorders, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology). In 2021, Oncology is the largest segment in this market. Factors such as increasing number of research studies on cancer therapeutics and the emerging companies and the high incidence and prevalence of cancer is driving the market.

"Asia Pacific: The fastest-growing region in the clinical trial supplies market"

On the basis of region, the clinical trial supplies market is segmented into North America, Europe, Asia Pacific, Rest of world. During the forecast period, the Asia Pacific market is expected to be the fastest-growing regional segment. Factors such as growing investments and expansions by key companies in countries such as China, India, and South Korea.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80% and Demand Side 20%
  • By Designation: C-level - 20%, Executives - 25%, and Managers - 55%
  • By Region: Asia Pacific -50%, North America -30%, Europe -10%, RoW -10%

Lists of Companies Profiled in the Report:

  • Thermo Fisher (US)
  • Catalent, Inc. (US)
  • Parexel (US)
  • Eurofins (France)
  • Piramal Pharma Solutions (India)
  • Almac Group (UK)
  • PCI Pharma Services (US)
  • PRA Health Sciences (US)
  • Biocair (UK), Eurofins (France)
  • Marken (US)
  • Infosys (India)
  • Liveo Research (India)
  • Capsugel (a Lonza Group company) (Switzerland)
  • KLIFO A/S (Denmark)
  • Clinigen (UK)
  • Ancillare (US)
  • N-SIDE (Belgium)
  • ADAllen (UK)
  • Durbin (UK)
  • Recipharm (Sweden)
  • OCT Group LLC. (Latvia)
  • Corex Logistics (Ireland)
  • Acnos Pharma GMBH (Germany)
  • Clinical Services International (UK)
  • Movianto (Ireland)

Research Coverage:

This report provides a detailed picture of the clinical trial supplies market. It aims at estimating the size and future growth potential of the market across different segments such as the service, end user, phases, therapeutic areas, type and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, and opportunities.

Product Code: PH 3772

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC SCOPE
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL SUPPLIES MARKET
  • 2.2 MARKET DATA ESTIMATION AND TRIANGULATION
    • FIGURE 4 DATA TRIANGULATION METHODOLOGY
  • 2.3 MARKET ESTIMATION METHODOLOGY
    • FIGURE 5 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS
    • FIGURE 6 CLINICAL TRIAL SUPPLIES MARKET: FINAL MARKET SIZE (USD BILLION)
  • 2.4 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS
    • FIGURE 8 FINAL CAGR PROJECTIONS (2022-2027)
  • 2.5 INSIGHTS FROM PRIMARIES
    • FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.6 RESEARCH ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2021
    • FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY THERAPEUTIC AREA, 2021
    • FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2021
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET

4 PREMIUM INSIGHTS

  • 4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
    • FIGURE 16 INCREASING R&D EXPENDITURE OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE AND COUNTRY (2021)
    • FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR LARGEST SHARE OF CLINICAL TRIAL SUPPLIES MARKET IN NORTH AMERICA
  • 4.3 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN CLINICAL TRIAL SUPPLIES MARKET FROM 2022 TO 2027

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.3 IMPACT ANALYSIS
    • 5.3.1 DRIVERS
      • 5.3.1.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies
      • 5.3.1.2 Increasing number of registered clinical trials
    • FIGURE 20 REGISTERED CLINICAL STUDIES, 2011-2022
      • 5.3.1.3 Increasing decentralization of clinical trials
    • 5.3.2 RESTRAINTS
      • 5.3.2.1 High cost of drug development
    • 5.3.3 OPPORTUNITIES
      • 5.3.3.1 Emerging markets
    • 5.3.4 CHALLENGES
      • 5.3.4.1 High cost of clinical trials
  • 5.4 RANGES/SCENARIOS
    • FIGURE 21 SCENARIOS OF CLINICAL TRIAL SUPPLIES MARKET
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS OF CLINICAL TRIAL SUPPLIES MARKET
  • 5.7 ECOSYSTEM/MARKET MAP
  • 5.8 SUPPLY CHAIN
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 2 PORTER'S FIVE FORCES ANALYSIS: CLINICAL TRIAL SUPPLIES MARKET
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • 5.9.5 DEGREE OF COMPETITION
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 INTRODUCTION
  • 5.11 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 3 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 INTERACTIVE RESPONSE TECHNOLOGY (IRT)
  • 5.13 PATENT ANALYSIS
    • FIGURE 23 TOP PATENTS IN CLINICAL TRIAL SUPPLIES MARKET

6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 4 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
  • 6.2 LOGISTICS AND DISTRIBUTION
    • 6.2.1 EVOLVING TREATMENT PROTOCOLS AND DATA SECURITY CHALLENGES TO DRIVE DEMAND FOR LOGISTICS AND DISTRIBUTION SERVICES
    • TABLE 5 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 6 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 7 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 8 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS AND DISTRIBUTION SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 STORAGE AND RETENTION
    • 6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH
    • TABLE 9 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 10 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 12 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE AND RETENTION SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.4 PACKAGING, LABELING, AND BLINDING
    • 6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE MARKET
    • TABLE 13 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.5 MANUFACTURING
    • 6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING THEIR MANUFACTURING CAPACITIES TO DRIVE MARKET
    • TABLE 17 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 18 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 19 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.6 COMPARATOR SOURCING
    • 6.6.1 INTENSE MARKET COMPETITION, REGULATORY PRESSURE, AND RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH
    • TABLE 21 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 22 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 23 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.7 OTHER SERVICES
    • TABLE 25 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 26 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 27 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)

7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE

  • 7.1 INTRODUCTION
    • TABLE 29 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
  • 7.2 PHASE III
    • 7.2.1 PHASE III TRIALS INVOLVE LARGE PATIENT POPULATION
    • TABLE 30 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 31 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 32 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 PHASE II
    • 7.3.1 PHASE II CLINICAL TRIALS HELP IN UNDERSTANDING EFFECTIVENESS OF DRUG AND FURTHER EVALUATING ITS SAFETY
    • TABLE 34 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 36 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 PHASE I
    • 7.4.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND LOGISTICS PLAY VITAL ROLE IN PHASE I CLINICAL TRIALS
    • TABLE 38 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 40 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 PHASE IV
    • 7.5.1 PHASE IV STUDIES ALLOW RESEARCHERS TO OBSERVE LONG-TERM EFFECTS OF PARTICULAR DRUGS IN LARGER POOL OF PATIENTS
    • TABLE 42 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 43 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 44 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.6 BA/BE STUDIES
    • 7.6.1 PATENT EXPIRATION OF DRUGS TO INCREASE DEMAND FOR BA/BE STUDIES
    • TABLE 46 CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 47 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2020-2027 (USD MILLION)

8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE

  • 8.1 INTRODUCTION
    • TABLE 50 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.2 SMALL-MOLECULE DRUGS
    • 8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET
    • TABLE 51 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 52 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 54 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 BIOLOGIC DRUGS
    • 8.3.1 BIOLOGIC DRUGS HAVE RELATIVELY LOW RATE OF ATTRITION COMPARED TO SMALL-MOLECULE DRUGS
    • TABLE 55 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 56 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 57 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 MEDICAL DEVICES
    • 8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO DRIVE MARKET
    • TABLE 59 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 60 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2020-2027 (USD MILLION)

9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
    • TABLE 63 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
  • 9.2 ONCOLOGY
    • 9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET
    • TABLE 64 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 65 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 66 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.3 CNS AND MENTAL DISORDERS
    • 9.3.1 INCREASING CASES OF MENTAL DISORDERS TO DRIVE MARKET
    • TABLE 68 CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 69 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 70 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 71 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CNS AND MENTAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.4 CARDIOVASCULAR DISEASES
    • 9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH
    • TABLE 72 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 73 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 74 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.5 DIGESTIVE DISORDERS
    • 9.5.1 INCREASING R&D FOR DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE MARKET
    • TABLE 76 CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 77 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 78 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.6 INFECTIOUS DISEASES
    • 9.6.1 EMERGENCE OF NEW INFECTIONS SUCH AS EBOLA, ZIKA, AND COVID-19 ACCELERATED EFFORTS TO DEVELOP NEW DRUGS
    • TABLE 80 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 81 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 82 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.7 METABOLIC DISORDERS
    • 9.7.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE GROWTH
    • TABLE 84 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 86 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.8 BLOOD DISORDERS
    • 9.8.1 GROWTH IN NUMBER OF HEMOPHILIA PATIENTS TO BOOST PRODUCTION OF MACROMOLECULES AND RECOMBINANT FACTORS
    • TABLE 88 CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 89 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 90 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.9 IMMUNOLOGY
    • 9.9.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL NEED FOR PROCURING CLINICAL TRIAL SUPPLIES
    • TABLE 92 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 93 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 94 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.10 OTHER THERAPEUTIC AREAS
    • TABLE 96 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 97 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 98 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020-2027 (USD MILLION)

10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 100 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    • 10.2.1 INCREASING R&D INVESTMENTS TO BOOST OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    • TABLE 101 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 102 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 103 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 10.3 CONTRACT RESEARCH ORGANIZATIONS
    • 10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS
    • TABLE 105 CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 106 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 107 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 108 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 10.4 MEDICAL DEVICE COMPANIES
    • 10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET
    • TABLE 109 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 110 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 111 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)

11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 113 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 11.2 NORTH AMERICA
    • TABLE 114 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 115 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 116 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 117 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 118 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 119 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Increasing R&D investments to drive market
    • TABLE 120 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 121 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 122 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 123 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 124 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth
    • TABLE 125 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 126 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 127 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 128 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 129 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 130 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 131 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 132 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 133 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 134 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 135 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Growing number of sponsored trials to boost demand for clinical trial supplies
    • TABLE 136 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 137 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 138 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 139 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 140 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth
    • TABLE 141 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 142 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 143 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 144 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 145 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Presence of leading pharmaceutical companies to support market growth
    • TABLE 146 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 147 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 148 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 149 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 150 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Increasing number of drug approvals to drive market for clinical trial supplies
    • TABLE 151 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 152 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 153 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 154 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 155 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Increasing biologics production to support market growth
    • TABLE 156 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 157 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 158 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 159 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 160 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.6 SWITZERLAND
      • 11.3.6.1 Growing R&D efforts to provide growth opportunities for clinical trial supplies market
    • TABLE 161 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 162 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 163 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 164 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 165 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 166 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 167 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 168 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 169 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 170 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • TABLE 171 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 173 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 174 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 175 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 176 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Favorable government regulations to boost market growth
    • TABLE 177 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 178 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 179 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 180 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 181 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Government initiatives for drug innovation to support market growth
    • TABLE 182 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 183 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 184 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 185 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 186 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Low manufacturing costs and skilled workforce-factors attracting outsourcing and investment to India
    • TABLE 187 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 188 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 189 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 190 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 191 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.4 AUSTRALIA
      • 11.4.4.1 Favorable location for drug discovery due to presence of many research institutes
    • TABLE 192 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 193 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 194 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 195 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 196 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.5 SOUTH KOREA
      • 11.4.5.1 Seoul among world's largest clinical research centers
    • TABLE 197 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 198 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 199 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 200 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 201 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.6 SINGAPORE
      • 11.4.6.1 Presence of world-class infrastructure to drive market
    • TABLE 202 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 203 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 204 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 205 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 206 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.7 REST OF ASIA PACIFIC
    • TABLE 207 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 208 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 209 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 210 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 211 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 11.5 REST OF THE WORLD
    • TABLE 212 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 213 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 214 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 215 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 216 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 217 REST OF THE WORLD: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.5.1 LATIN AMERICA
      • 11.5.1.1 Growing R&D expenditure in pharmaceutical and biopharmaceutical sector to drive market
    • TABLE 218 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 219 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 220 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 221 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 222 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.5.2 MIDDLE EAST AND AFRICA
      • 11.5.2.1 Growing presence of pharmaceutical companies to drive market
    • TABLE 223 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2020-2027 (USD MILLION)
    • TABLE 224 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2020-2027 (USD MILLION)
    • TABLE 225 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 226 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2020-2027 (USD MILLION)
    • TABLE 227 MIDDLE EAST AND AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 27 CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
    • FIGURE 28 KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 29 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY KEY PLAYER, 2021
  • 12.5 COMPANY EVALUATION QUADRANT
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 30 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION QUADRANT, 2021
  • 12.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 RESPONSIVE COMPANIES
    • 12.6.4 DYNAMIC COMPANIES
    • FIGURE 31 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021
  • 12.7 COMPETITIVE BENCHMARKING
    • TABLE 228 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
    • 12.7.1 FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 229 SERVICE FOOTPRINT OF COMPANIES
    • TABLE 230 REGIONAL FOOTPRINT OF COMPANIES
  • 12.8 COMPETITIVE SCENARIO
    • TABLE 231 SERVICE LAUNCHES
    • TABLE 232 DEALS
    • TABLE 233 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 MAJOR PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 13.1.1 THERMO FISHER SCIENTIFIC
    • TABLE 234 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.2 CATALENT, INC.
    • TABLE 235 CATALENT, INC.: BUSINESS OVERVIEW
    • FIGURE 33 CATALENT, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.3 MARKEN (SUBSIDIARY OF UPS)
    • TABLE 236 UPS: BUSINESS OVERVIEW
    • FIGURE 34 UPS: COMPANY SNAPSHOT (2021)
    • 13.1.4 EUROFINS SCIENTIFIC
    • TABLE 237 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 35 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
    • 13.1.5 PRA HEALTH SCIENCES (SUBSIDIARY OF ICON PLC)
    • TABLE 238 ICON PLC: BUSINESS OVERVIEW
    • FIGURE 36 ICON PLC: COMPANY SNAPSHOT (2021)
    • 13.1.6 PAREXEL INTERNATIONAL CORPORATION
    • TABLE 239 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
    • 13.1.7 BIOCAIR
    • TABLE 240 BIOCAIR: BUSINESS OVERVIEW
    • 13.1.8 ALMAC GROUP
    • TABLE 241 ALMAC GROUP: BUSINESS OVERVIEW
    • 13.1.9 PIRAMAL PHARMA SOLUTIONS
    • TABLE 242 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
    • FIGURE 37 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
    • 13.1.10 INFOSYS
    • TABLE 243 INFOSYS: BUSINESS OVERVIEW
    • FIGURE 38 INFOSYS: COMPANY SNAPSHOT (2022)
    • 13.1.11 PCI PHARMA SERVICES
    • TABLE 244 PCI PHARMA SERVICES: BUSINESS OVERVIEW
    • 13.1.12 LIVEO RESEARCH
    • TABLE 245 LIVEO RESEARCH: BUSINESS OVERVIEW
    • 13.1.13 CAPSUGEL (ACQUIRED BY LONZA)
    • TABLE 246 LONZA: BUSINESS OVERVIEW
    • FIGURE 39 LONZA: COMPANY SNAPSHOT (2021)
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 OCT GROUP LLC
    • 13.2.2 COREX LOGISTICS
    • 13.2.3 ACNOS PHARMA GMBH
    • 13.2.4 CLINICAL SERVICES INTERNATIONAL
    • 13.2.5 KLIFO
    • 13.2.6 CLINIGEN LIMITED
    • 13.2.7 ANCILLARE, LP
    • 13.2.8 N-SIDE
    • 13.2.9 ADALLEN PHARMA
    • 13.2.10 DURBIN
    • 13.2.11 RECIPHARM AB
    • 13.2.12 MOVIANTO

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!